NCT07459296 2026-03-16
Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC
First Affiliated Hospital of Guangxi Medical University
Phase 3 Recruiting
Clinical Trials
23 trialsNCT05171660 2026-02-17
Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3 Active not recruiting
NCT07371611 2026-01-28
Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Recruiting
NCT07306663 2025-12-29
ESO-Nanjing7
Jiangsu Cancer Institute & Hospital
Phase 3 Active not recruiting
NCT07186621 2025-09-22
Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Recruiting
NCT05357846 2025-06-12
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
Sun Yat-sen University
Phase 3 Recruiting
NCT06794086 2025-05-13
SPARKLE-L
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3 Recruiting
NCT06925243 2025-04-22
Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Lanzhou University Second Hospital
Phase 3 Recruiting
NCT06900218 2025-04-02
PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT05549037 2025-02-19
PACIFIC15
Hunan Province Tumor Hospital
Phase 3 Recruiting
NCT06485557 2024-07-03
A Prospective Cohort Study of Neoadjuvant Chemotherapy Plus Sintillumab in the Treatment of Resectable NSCLC
Tang-Du Hospital
Phase 3 Not yet recruiting
NCT06089369 2024-04-30
Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion
Tongji Hospital
Phase 3 Not yet recruiting
NCT05918094 2024-01-26
Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
Sun Yat-sen University
Phase 3 Recruiting
NCT06161909 2023-12-08
Postoperative Immune Maintenance Therapy for Esophageal Squamous Cell Carcinoma After Radical Resection
Fujian Medical University Union Hospital
Phase 3 Unknown
NCT06089382 2023-10-18
A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection
Tongji Hospital
Phase 3 Not yet recruiting
NCT06031597 2023-09-13
Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy
Zhejiang Cancer Hospital
Phase 3 Unknown
NCT05608200 2023-05-31
Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC
Second Affiliated Hospital of Guangzhou Medical University
Phase 3 Recruiting
NCT03700476 2023-03-28
CONTINUUM
Sun Yat-sen University
Phase 3 Unknown
NCT05236972 2022-12-30
PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer
Sun Yat-sen University
Phase 3 Recruiting
NCT05429463 2022-12-14
neoSCORE â…¡
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3 Recruiting
NCT05648071 2022-12-13
SPBPDC
Qianfoshan Hospital
Phase 3 Unknown
NCT05244798 2022-10-25
Sintilimab Plus NCT or NCRT Versus NCRT for ESCC
Sichuan Cancer Hospital and Research Institute
Phase 3 Not yet recruiting
NCT05429684 2022-06-23
Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer
First Affiliated Hospital Xi'an Jiaotong University
Phase 3 Unknown